News

Solutions should address staffing shortages and burnout.

According to the company, the ReCLAIM-2 study of elamipretide demonstrates a correlation between ellipsoid zone dysfunction and vision.

According to the company, a clinical trial evaluating Nyxol eye drops for night vision disturbances met FDA-agreed primary endpoint with subjects gaining 3 lines of low-contrast distance vision under dim light conditions compared to placebo.

According to the companies, Kala will receive $60 million in upfront payment, and could be eligible to receive additional sales-based milestone payments.

Attention to details can help to deliver patients consistent, quality outcomes.

Clinicians discover the ptotic facial side of the face was the nondominant side of the face in a recent study.

There’s a new alternative to LASIK in the United States. In March of 2022, the FDA approved STAAR Surgical’s EVO/EVO+ VISIAN Implantable Collamer Lens (ICL) and Toric Implantable Collamer Lens (TICL).

On this part two episode with Colin Carr, founder and CEO of CARR, we hear more about commercial real estate dos and don'ts when managing the space of your practice. Tune in now for the Q&A with Ophthalmology Times® executive editor, David Hutton.

The expansion includes the construction of the Jeffrey and Patricia Cole Building at Cole Eye Institute and renovation of the existing building.

Tennessee Academy of Ophthalmology’s doctor of the month shares what excites him about ophthalmology, his biggest career challenge, and chocolate as his favorite comfort food.

Participate by May 20 in the annual Ophthalmic Business and Leadership Trends Survey for 2022.

Investigators find the recognition could improve surveillance of the disease.

In a patient survey, 66% of respondents said AI plays a large role in their diagnosis and treatment and thought it was important.

In a paper, investigators identified strategies used by patients to reduce the cost of therapy and its impact on adherence to treatment Patients may be reluctant to disclose challenges regarding adherence to dry eye disease therapy, as well as fears of worsening quality of life.

Two grants will be available, each offering $150,000 to scientists focusing on glaucoma research who have already received their first independent federal National Institutes of Health (NIH) grant and are collecting new and novel data to apply for a second R01.

BRIM Biotechnology Inc. has entered into a new strategic partnership with Ora Inc. for the late-stage clinical development of lead drug candidate BRM421 for dry eye syndrome (DES).

Philip Ruzycki, PhD, receives a career development award that will provide $350,000 to support his laboratory over the next 4 years.

TAKE-HOME: This affordable device allows the view through a slit lamp to be shared in real time or recorded, for teaching and reference purposes.

For health care workers, the pandemic has led to increased burnout, concerns about workplace safety, and staffing shortages that threaten not only patient care but also the entire provider ecosystem.

A discovery by investigators at the National Eye Institute sheds light on tissue targeted by age-related macular degeneration and other diseases.

The Eye Van, operated by Vision Loss Rehabilitation Canada, is a mobile medical clinic that delivers eye care in northern Ontario communities where ophthalmology services aren't readily available.

Investigators note that the capacity to visualize corneal nerves of the sub-basal plexus and stroma in real time and without requiring use of contrast agents allows for longitudinal studies that can track nerve density and arborization in the same subjects over time.

The study found that if certain forms of nystagmus that are seen in patients, then there is a higher chance of poor binocular visual function, as well as higher interocular suppression.

The study evaluates three separate cases, each which experiences irreversible changes in their corneal structure caused by challenges in getting timely treatment due to various reasons, including insurance, lost to follow up, and the coronavirus pandemic.

The company is partnering with leading ophthalmology practices focused on improving patient outcomes. OMNY solutions are derived from electronic health record data and provide valuable information on the evolving treatment paradigm for patients with ophthalmic disease, including difficult to obtain insights on the rationale behind treatment decisions, and the impact of social determinants of health on care delivery and outcomes.

The American Academy of Ophthalmology applauded Congress for reaching the 290-consponsor milestone for the proposal. By reaching the two-thirds majority of bipartisan support in Congress, the bill is eligible for inclusion on the Consensus Calendar under new rules that were established in 2019.

Colin Carr, founder and CEO of CARR, chats with Ophthalmology Times' David Hutton in this part one episode of the EyePod. Carr hits on some hot real estate topics in the healthcare industry, including top mistakes healthcare providers make with their office space, how to decide whether you're going to purchase or lease, and how healthcare providers can save $100k or more on their next lease renewal.

At ARVO 2022 in Denver, Colorado, Timothy Blenkinsop, MD, presented “3D Eye Organoids with Distinct Cornea.” His presentation outlined how these organoids have developed sophisticated cornea structures.